David Einhorn's ROIV Position Overview
David Einhorn (via Dme Capital Management, Lp) currently holds 2.3M shares of Roivant Sciences Ltd. (ROIV) worth $34.43 M, representing 1.35% of the portfolio. First purchased in 2024-Q1, this short-term holding has been held for 7 quarters.
Based on 13F filings, David Einhorn has maintained this position in ROIV for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2024, adding 620.5K shares. Largest reduction occurred in Q3 2025, reducing 2.3M shares.
Analysis based on 13F filings available since 2013 Q2
David Einhorn's Roivant Sciences (ROIV) Holding Value Over Time
Track share changes against reported price movement
Quarterly Roivant Sciences (ROIV) Trades by David Einhorn
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2024 | +4.19 M | Add 0.00% | 4.19 M | $10.54 |
| Q2 2024 | +620,470 | Add 14.81% | 4.81 M | $10.57 |
| Q3 2024 | +497,080 | Add 10.33% | 5.31 M | $11.54 |
| Q4 2024 | -36,973 | Reduce 0.70% | 5.27 M | $11.83 |
| Q1 2025 | +170,100 | Add 3.23% | 5.44 M | $10.09 |
| Q2 2025 | -890,110 | Reduce 16.36% | 4.55 M | $11.27 |
| Q3 2025 | -2.28 M | Reduce 50.00% | 2.28 M | $15.13 |
David Einhorn's Roivant Sciences Investment FAQs
David Einhorn first purchased Roivant Sciences Ltd. (ROIV) in Q1 2024, acquiring 4,190,490 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
David Einhorn has held Roivant Sciences Ltd. (ROIV) for 7 quarters since Q1 2024. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
David Einhorn's largest addition to Roivant Sciences Ltd. (ROIV) was in Q1 2024, adding 4,190,490 shares worth $44.17 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, David Einhorn's firm, Dme Capital Management, Lp, owns 2,275,529 shares of Roivant Sciences Ltd. (ROIV), valued at approximately $34.43 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Roivant Sciences Ltd. (ROIV) represents approximately 1.35% of David Einhorn's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
David Einhorn's peak holding in Roivant Sciences Ltd. (ROIV) was 5,441,167 shares, as reported at the end of Q1 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.